In June, the Advera analyst team combed through prescription and patient population data supplied by our partners at Evaluate Pharma to update our RxScore and RxCost analytics site-wide. The end result yielded 53 drugs with first-time RxScores and 69 drugs with first-time RxCosts.
Many of the drugs with new RxScores and RxCosts were approved in 2014 and 2015, adding even more decision making power to our health and hospital system clients who are evaluating those newer medications.
For those of you who need a refresher, RxScore is a 1-100 scale that measures a drug’s potential risk per patient based on serious side effects and poor patient outcomes (lower scores indicate safer profiles, while higher scores indicate less safe profiles per patient exposed to the product). RxCost quantifies the downstream medical costs incurred from those same adverse events and poor patient outcomes by mapping them to costing data from the Healthcare Cost and Utilization Project (HCUP).
Our clients use these analytics to assess the overall safety of medications in relation to one another, and to determine future cost savings during formulary reviews. RxScore is used to compare drugs within the same indication, drug class, or mechanism of action. With RxScore, we often see trends across groups of drugs that act on the body in the same way, or similarly tolerable safety profiles for drugs used to treat specific indications. For example, riskier safety profiles are more tolerated in medications for very sick patients with rare diseases since they have few if any other treatment options.
The RxScore chart below shows safety scores for all of the Multiple Myeloma drugs. You can see drugs with first-time RxScores outlined in yellow, with Ninlaro (ixazomib) having the lowest score at 61.83 and Farydak (panobinostat) having the highest, least safe score at 100 points. While most of the serious adverse events contributing to the highest scoring Multiple Myeloma drugs are listed on their drug labels (i.e. they are known potential risks), there are also reported cases of pancytopenia, and cerebrovascular accident (stroke), hemorrhage, bone fracture, etc. which are not listed on their respective drug labels. Our analysts put in the work of mining each drug's label so our clients can quickly identify these known and unknown risks and take them into account when analyzing the safety of medications.
Of the drugs with new RxScores, Farydak (panobinostat) and Blincyto (blinatumomab) were considered the riskiest with scores of 100 and 98.12, respectively. Approximately 58% of drugs with first-time RxScores had scores above 50, indicating less safe adverse event profiles in those medications. You can access a copy of our full RxScore/RxCost update report here.
If you’d like to know more about how other health and hospital systems are utilizing these data, feel free to contact us.
Andrea R. Demakas, Product Specialist